Antibody treatment for multiple system atrophy
Part of Brain & nervous system clinical trials.
This trial tests a new antibody therapy that may target and remove abnormal proteins in the brain linked to Multiple System Atrophy (MSA). It aims to see if the treatment is safe and whether it can help slow the progression of the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 45 and 75 years old
- Have a confirmed diagnosis of probable or possible Multiple System Atrophy (MSA)
- Symptoms started within the last 2 years
- Be medically stable, with no major changes in your condition in the past 4 weeks
- Not have other serious brain conditions like Parkinson's disease or stroke
- No significant memory or mental health issues, and be able to give informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new surgery that connects lymphatic vessels to veins in the neck, which may help improve symptoms of multiple system atrophy (MSA), a rare brain disorder that affects movement and balance. The goal is to see if this surgery is safe and effective, and it might offer a new way to slow the disease progression.
This early-phase trial tests a new drug called ALT001 for people with multiple system atrophy (MSA). It aims to see if the drug is safe and may help slow the disease.
This trial tests a new stem cell treatment for people with multiple system atrophy (MSA), a rare brain disorder that affects movement and automatic body functions. The treatment uses stem cells from healthy donors, which may help slow down the disease.
This trial tests a nasal spray called Foralumab for people with multiple system atrophy (MSA). The goal is to see if the spray can help reduce symptoms or slow the disease. It is for people who are otherwise healthy enough to safely participate.
This study tests whether a drug called butylphthalide can safely help people with multiple system atrophy (MSA), a rare brain disorder that affects movement and automatic body functions like blood pressure. Participating may help slow the progression of symptoms and improve quality of life.
This study looks at how the body handles blood sugar (insulin resistance) in people with multiple system atrophy (MSA). Results may help doctors understand the disease better and explore new ways to monitor or treat it.
Hear when a new Multiple System Atrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.